17.80 +0.08 (0.45%)
After hours: 5:34PM EST
|Bid||17.77 x 800|
|Ask||17.80 x 800|
|Day's Range||16.65 - 19.20|
|52 Week Range||2.35 - 23.34|
|Beta (3Y Monthly)||-0.01|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 4, 2017 - May 8, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||34.80|
CNBC's Meg Tirrell sits down with Amarin CEO John Thero to discuss Amarin dropping after posting mixed results in a drug trial.
Investors are the least optimistic on tech stocks like these since the depths of the financial crisis and are instead directing attention to another corner of the market: healthcare. REDUCE-IT suggests that the residual 65-75% cardiovascular risk beyond cholesterol management can be significantly lowered with Vascepa in studied patients.
In the first nine months of 2018, Amarin reported revenues of $151.3 million, which is 20.0% YoY growth. Analysts expect Amarin to report a gross margin of 75.43% in 2018, which will be a rise of 25 basis points YoY. The company is expected to witness a gross margin of 76.67% in 2019, which will be an improvement by 123 basis points YoY.
Currently, Amarin (AMRN) is focused on creating awareness for Vascepa across new territories. According to Amarin’s third-quarter earnings conference call, the company is initially targeting territories that have the potential to become profitable in a short timeframe. Amarin has been targeting ~20,000 general practitioners to increase Vascepa’s adoption. General practitioners are the first physicians that patients visit when they’re suffering from high cardiovascular risk. General practitioners account for almost 85% of the total physicians that Amarin is targeting. Among the remaining physicians, ~7% are cardiologists and 5% are endocrinologists.
NEW YORK / ACCESSWIRE / November 14, 2018 / U.S. equities closed down on Wednesday as tech giant Apple closed near bear-market territory and another drop in oil prices raised concerns of a global economic ...
President and CEO of Amarin Corp Plc (NASDAQ:AMRN) John F Thero sold 607,611 shares of AMRN on 11/12/2018 at an average price of $19.07 a share.
According to Amarin’s (AMRN) third-quarter earnings conference call, the company secured prescription approval rates of 75% for Vascepa from Managed Care organizations—similar to the approval rates witnessed by generic Lovaza. The company has been witnessing rapid revenue growth for Vascepa, despite a narrow label and low salesforce. Amarin is focused on capacity expansion, which could support more than $1.0 billion worth of Vascepa’s net revenues in 2019.
In the third-quarter earnings conference call, Amarin (AMRN) didn’t provide any revenue guidance for the fourth quarter, 2018, or 2019. After the REDUCE-IT trial results, Amarin aims to increase the number of sales representatives in the US market to 400 by the beginning of 2019. According to Amarin’s third-quarter earnings conference call, the expanded sales force and primary results published in the American Heart Association presentation on November 10 are expected to drive Vascepa’s revenue growth in future quarters.
U.S. stock futures are inching higher this morning as traders grapple with the ongoing implications of a meltdown in the oil markets. In the options pits, calls slightly outpaced puts while overall volume levels ended the day near average levels. Specifically, about 18.9 million calls and 17.3 million puts changed hands on the session.
The S&P 500 closed at 2722.18 yesterday, down 0.15%, led lower by Amarin Corporation (NASDAQ:AMRN) and Apple (NASDAQ:AAPL). Rather, it’s stock charts of HollyFrontier (NYSE:HFC), PPL (NYSE:PPL) and Home Depot (NYSE:HD) that hold the most promise, as they’ve all formed some familiar setups. It has probably got more to do with the brewing weakness with the whole energy sector than with HollyFrontier in particular.
On November 12, Amarin (AMRN) stock closed at $19.82, which is 5.84% lower than its previous closing price. On November 10, Amarin issued a press release announcing favorable primary results from the cardiovascular outcomes trial—REDUCE-IT. Despite the favorable outcomes from REDUCE-IT, the stock has been impacted negatively due to queries raised by researchers and cardiologists about the use of mineral oil as a placebo in the cardiovascular outcomes trial.
NEW YORK , Nov. 13, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN). Such investors ...
Amarin (AMRN) posts detailed data from a late-stage cardiovascular outcomes study on its fish oil drug Vascepa. The stock takes a hit.
People "will appreciate" what the Vascepa capsule does once they "understand our data better," Amarin CEO John Thero says. The biopharmaceutical firm's stock was down for much of the day Monday after results of a major clinical trial were revealed over the weekend. Amarin AMRN CEO John Thero shrugged off the stock's decline on Monday, telling CNBC that any investor concerned about its latest clinical trial should take a better look at the data.
The REDUCE-IT trial was a global study of 8,179 statin-treated adults with elevated cardiovascular risk, and it studied Vascepa 4gm/day as compared to placebo over a median follow-up time of 4.9 years. Amarin's Vascepa capsules are chemically icosapent ethyl and contain Omega-3 acid known as EPA in ethyl-ester form. Vascepa was approved by the FDA in 2012 to treat high levels of triglycerides in blood, and data from the recent trial is intended to be used to support a regulatory filing for the expanded indication of improving cardiovascular outcomes.
NEW YORK, NY / ACCESSWIRE / November 12, 2018 / U.S. markets plunged Friday, with the Dow dropping over 200 points, as falling oil prices raised global economic concerns. The Nasdaq Composite Index decreased 1.65 percent higher to close at 7,406.90. According to Willie Delwiche, investment strategist at R.W. Baird, “Oil being down could be a sign that the global economy is in a tough spot.” “The initial reaction to lower oil prices has been that they’ll be a boon for the middle class,” Delwiche said that the view could be inaccurate considering that consumer confidence doesn’t have more chances to grow, and because a smaller part of the American consumer’s budget goes to gasoline than it has in the previous years.
HLS Therapeutics Announces that Amarin's Vascepa ® (icosapent ethyl) Demonstrates 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attack and Stroke in REDUCE-IT™, which ...
Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes Study of a Drug Intended to Address Residual Cardiovascular Risk Remaining After ...